GlobalData on MSN3d
Regeneron’s Dupixent approved as first adolescent CRSwNP treatmentThe safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.
Zacks.com on MSN2d
Regeneron, SNY Win FDA Approval for a Broader Dupixent LabelRegeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved blockbuster drug Dupixent (dupilumab) for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) for a broader ...
Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with an inflammatory skin disease in a ...
Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. | It was a busy day for Sanofi and ...
13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab ...
Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster ...
Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria (CSU), Sanofi and ...
2d
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved blockbuster drug Dupixent (dupilumab) for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) for a broader ...
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback